Marfan syndrome is a rare hereditary connective tissue disorder primarily affecting the heart, eyes, and skeletal system. This condition is caused by genetic mutations that lead to abnormalities in the elastic fibers of various tissues, resulting in organ dysfunction and structural fragility. Common symptoms include elongated limbs, cardiovascular abnormalities, and visual problems, which can be life-threatening in severe cases.
This syndrome was first described in 1896 by French physician Antoine Marfan and is now classified as a key type of connective tissue disorder. It affects approximately 1 in 5,000 to 10,000 individuals worldwide, with similar prevalence in males and females. Although there is currently no cure, early diagnosis and regular monitoring can effectively control symptoms and delay the progression of complications.
The primary cause of Marfan syndrome is mutations in the FBN1 gene, which encodes a protein called fibrillin-1. This protein is a crucial component of connective tissue. When its structure is abnormal, it compromises the strength and elasticity of connective tissues throughout the body. About 75-80% of cases are inherited, with the remainder resulting from de novo mutations.
The genetic pattern is mainly autosomal dominant, meaning that inheriting the mutated gene from one parent can cause the disorder. However, phenotypic severity can vary among individuals, even within the same family. Environmental factors such as pregnancy, vigorous exercise, or stress may trigger worsening of cardiovascular complications.
Risk factors include:
The presentation of symptoms is highly diverse and can affect the entire connective tissue system. The main symptoms can be categorized into three systems:
Other common symptoms include:
The progression speed varies among individuals; some may remain stable for decades, but cardiovascular complications can suddenly worsen. Regular echocardiographic monitoring is an important tool for assessing disease progression.
Diagnosis involves clinical assessment combined with auxiliary examinations. Diagnostic criteria include:
Clinical evaluation includes detailed family history inquiry and comprehensive physical examination. Cardiac auscultation may reveal murmurs, ophthalmologic examination can detect lens dislocation, and X-rays may show scoliosis or thoracic deformities. Other connective tissue disorders with similar symptoms should be excluded during diagnosis.
Genetic testing has an accuracy rate of about 90%, but 10-20% of patients with typical symptoms may have negative results. Therefore, diagnosis should be based on multiple indicators. In special populations, such as suspected de novo mutations, expanded gene sequencing may be necessary.
The goal of treatment is to control symptoms, prevent complications, and slow disease progression. Non-surgical treatments include:
Surgical treatments mainly include:
Long-term management requires multidisciplinary team collaboration, including cardiologists, ophthalmologists, orthopedists, and geneticists. Patients should undergo echocardiographic follow-up every 6 to 12 months and regular ophthalmologic examinations. Lifestyle modifications such as smoking cessation and blood pressure control are fundamental management strategies.
Genetic prevention is key. Known family members should undergo genetic counseling and testing. Pregnant women can undergo prenatal diagnosis via amniocentesis. High-risk families can plan reproductive strategies through genetic counseling.
Symptomatic prevention includes:
Environmental management involves avoiding tobacco exposure to protect cardiovascular health, controlling comorbidities such as diabetes and hypertension, which can accelerate connective tissue degeneration. Regular multidisciplinary follow-up is essential for maintaining quality of life.
Seek immediate medical attention if you experience:
If you have suspicious symptoms such as markedly elongated limbs, scoliosis, or a family history, schedule a specialist assessment. Children with significantly tall stature and vision problems should undergo genetic counseling. Regular follow-up is necessary; if the aortic diameter increases by more than 0.3-0.5 cm per year, immediate consultation with a cardiovascular surgeon is recommended.
It is advised to undergo multidisciplinary evaluations every 6 to 12 months, including cardiac function, vision, and skeletal development monitoring. Cases suspected of de novo mutations should undergo genetic sequencing for confirmation to establish personalized management plans.
Typical features of Marfan syndrome include elongated limbs, spider-like fingers and toes, high myopia, or lens dislocation. If there are similar cases in the family or if you experience symptoms such as heart murmurs or scoliosis, early medical consultation for genetic testing and professional assessment is recommended.
Why are heart valve abnormalities a life-threatening risk in Marfan syndrome?Patients often have aortic aneurysms or dissections, which can lead to acute heart failure. Regular echocardiographic examinations can detect abnormalities early. Surgical repair of valves or the aorta can significantly reduce the risk of death.
What high-risk activities should be avoided in daily life?Patients should avoid diving, weightlifting, contact sports, and activities that increase aortic pressure. Low-impact aerobic exercises such as swimming or cycling are recommended, and consulting a physician for a personalized exercise plan is advised before starting any new activity.
Does pregnancy worsen Marfan syndrome symptoms?Pregnancy can increase blood volume and alter hemodynamics, placing additional stress on the aorta and increasing the risk of dissection. Pre-pregnancy assessment by cardiologists and obstetricians is necessary; some patients may need surgery before considering pregnancy.
Are there any medications currently available that can directly halt the progression of Marfan syndrome?Beta-blockers (such as atenolol) can slow the rate of aortic dilation but do not cure the genetic defect. Research suggests that transforming growth factor-beta (TGF-β) inhibitors may improve connective tissue abnormalities, but these are still in clinical trials and should be used under medical supervision.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
